Coya Therapeutics (COYA) Return on Capital Employed (2023 - 2026)
Coya Therapeutics (COYA) reported Return on Capital Employed of 46.85% for Q1 2026, up 565.0% on a YoY basis from 7.05% in Q1 2025, and up 27.04% sequentially from 64.21% in Q4 2025.
Coya Therapeutics (COYA) Return on Capital Employed (2023 - 2026) Analysis & Trends
Coya Therapeutics (COYA) has 4 years of Return on Capital Employed data on file, last reported at 46.85% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 565.0% year-over-year to 46.85%; the trailing twelve-month figure through Mar 2026 stood at 46.85% (up 565.0% YoY), and the FY2025 full-year result was 54.64%, down 1039.0% from the prior year.
- Return on Capital Employed rose to 46.85% in Q1 2026, from 64.21% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 29.95% in Q1 2024 to a low of 103.04% in Q3 2023.
- A 4-year average of 58.0% and a median of 52.5% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 7099 bps in 2024 and slumped 4194 bps in 2025, its largest moves.
- Tracing COYA's Return on Capital Employed over 4 years: stood at 36.71% in 2023, then sank by 30 bps to 47.75% in 2024, then plunged by 34 bps to 64.21% in 2025, then rose by 27 bps to 46.85% in 2026.
- Business Quant data shows COYA's Return on Capital Employed at 46.85% in Q1 2026, 64.21% in Q4 2025, and 70.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Coya Therapeutics | 97.14 Mn | 46.42 Mn | - | -46.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.85% |
| Dec 31, 2025 | -64.21% |
| Sep 30, 2025 | -70.85% |
| Jun 30, 2025 | -71.98% |
| Mar 31, 2025 | -52.50% |
| Dec 31, 2024 | -47.75% |
| Sep 30, 2024 | -32.05% |
| Jun 30, 2024 | -30.05% |
| Mar 31, 2024 | -29.95% |
| Dec 31, 2023 | -36.71% |
| Sep 30, 2023 | -103.04% |
| Jun 30, 2023 | -73.49% |
| Mar 31, 2023 | -94.60% |